SerOptix
Technology Platform: Spectra-Molecular Informatics (SMI)
Overview
In
blood and other physiological fluids, spectral signals of thousands
of natural molecules combine to present a complex but unique signature.
When disease strikes, this molecular signature is altered. When
this alteration includes fluorescent molecules, then the molecular
signature based on intrinsic fluorescence distinguishes normal
from disease samples.
SerOptix'
technology detects the natural differences between normal and
diseased samples, and thereby provides pivotal new information
for the development of novel therapeutic and diagnostic products.
Our current technology probes the relatively untapped domain of
native or intrinsic fluorescence of biological fluids and tissues.
This technology uses the combined power of selective sample extraction,
mathematical algorithms and state of the art laser-based optical
systems to amplify the divergence between healthy and disease-derived
samples. Powerful computational methods adapted at SerOptix permit
us to see beyond the normal variations and identify previously
unrecognized molecular changes arising from, and causing disease.
Our approach preferentially surveys the many classes of small
molecules that are recognized to be major constituents of the
molecular signature of both physiological and patho-physiological
states and that are not the targets of genomic and proteomic approaches.
The
SerOptix technology offers a unique strategy for the rapid elucidation
of changes in molecular physiology for diseases where critical
information concerning the biological effects of a disease would
be valuable for the development of new diagnostic and therapeutic
agents. The value of the SerOptix technology can be realized at
several level of the discovery process and the company determines
the appropriate stages to out-license new intellectual property
based on the combined review of both scientific and business parameters.
The
coupling of multiple analytical tools permits us to establish
the specific molecular determinants producing the spectral changes
and, of equal importance, provides the essential elements of a
comprehensive information-base that may hold great value for the
rapid correlation of spectral patterns and physiological changes
associated with the specific disease target.
The central strategy for the acquisition, analysis and exploitation
of the native spectral information described above has been called:
Spectra-Molecular Informatics, or SMI, (described
below in detail) and represents the underlying engine for the
generation of new intellectual property on which SerOptix bases
its business strategy. The parallel creation of proprietary normal
and disease databases is expected to provide a sustainable portfolio
of spectral leads and molecular profiles to support a series of
disease-specific corporate relationships.
The
company has applied the SMI technology to the evaluation of samples-derived
from patients infected with Hepatitis C virus (HCV) as a Proof
of Performance of this technology platform. Sufficient spectral
data has been collected that demonstrates molecular differences
between normal and disease that we intend to develop further through
corporate partners into novel diagnostic or therapeutic products.
The company is evaluating the opportunity to isolate and identify
HCV-specific molecular markers as a further validation of the
SMI approach and to secure an intellectual property position around
these molecules for licensing and partner-based product development.
To support these efforts, further instrument development will
focus on the optimization and application of Intrinsic Fluorescence
Information Technology (INFLIT) systems for rapid acquisition
of spectral data of chromatographic peaks during elution as a
source of high value spectral data to complement the Spectral
Profiling steps of SMI.
Through
these efforts SerOptix intends to produce a panel of proprietary
disease-specific spectral and molecular leads, a comprehensive
database including normal and disease SMI data, and a powerful
discovery system, each offering significant utility and value
for the pharmaceutical and diagnostic development process.
Spectra-Molecular
Informatics (SMI) Application
Spectra-Molecular
Informatics provides a powerful platform for the identification
of disease-specific Molecular Targets from combined spectral,
chromatographic, and structural data. For any selected disease
program, the SMI approach sequentially engages specific elements
of our core technology, yielding several internal milestones and
a program portfolio of enhanced value for partnership and product
development.
The
application of SMI is implemented through a series of steps providing
increasingly specific spectral information and understanding of
molecular differences associated with a target disease. These
steps, described in greater detail through the links below, provide
the core data of the SMI database that will increase progressively
in complexity, information content, and value with the continued
expansion of our R&D programs and business strategies.
Spectra-Molecular
Informatics Process
- Spectral
Data Acquisition & Processing
- Identification
of Disease-Specific Spectral Signals
-
Molecules
Carrying Disease-Specific Spectral Properties
-
- Assays
for Drug Discovery, Therapeutic Product Development
and Diagnostic Applications
Spectra-Molecular
Informatics Database
[
About SerOptix ] [ The
SerOptix Process ]
[ Investment News ] [ Industry
News ] [ Media ]
[ Career Opportunities ] [ Contact
Us ][ Home ]
Copyright©
2000 SerOptix,Inc
All Rights Reserved
